Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature
Studying tissue-independent components of cancer and defining pan-cancer subtypes could be addressed using tissue-specific molecular signatures if classification errors are controlled. Since PAM50 is a well-known, United States Food and Drug Administration (FDA)-approved and commercially available b...
Main Authors: | Darío Rocha, Iris A. García, Aldana González Montoro, Andrea Llera, Laura Prato, María R. Girotti, Gastón Soria, Elmer A. Fernández |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/1/45 |
Similar Items
-
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
by: Ramona Erber, et al.
Published: (2022-08-01) -
Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases
by: Mariana Bustamante Eduardo, et al.
Published: (2019-06-01) -
Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
by: Soledad Ochoa, et al.
Published: (2020-05-01) -
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
by: Elisa Agostinetto, et al.
Published: (2021-06-01) -
Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification
by: Leandro Y. S. Okimoto, et al.
Published: (2024-03-01)